Search Result

Results for "

MDA-MB-468

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (3) Akt (4) Apoptosis (23) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Autophagy (4) Bcl-2 Family (1) Bcr-Abl (1) c-Myc (1) Calmodulin (1) Carbonic Anhydrase (2) Casein Kinase (1) CDK (14) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (3) DYRK (2) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) EGFR (1) Epigenetic Reader Domain (3) FAK (1) Fatty Acid Synthase (FASN) (1) FLT3 (1) Gli (1) Glutathione Peroxidase (1) GSK-3 (2) Hedgehog (1) HSP (6) HuR (1) JAK (2) MELK (2) MMP (1) Molecular Glues (1) Mps1 (1) mTOR (2) Necroptosis (1) NF-κB (1) PARP (3) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (3) Phosphoglycerate Dehydrogenase (PHGDH) (3) Phospholipase (1) PI3K (1) Pim (2) PIN1 (2) Polo-like Kinase (PLK) (3) PPAR (1) PROTACs (7) Proteasome (1) Pyroptosis (1) Reactive Oxygen Species (1) RIP kinase (2) SHP2 (2) Smo (1) Src (4) SRPK (1) STAT (8) Topoisomerase (1) TrxR (1) Tyrosinase (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (84) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Peptides

Natural
Products

Click Chemistry

Targets Recommended: SDCBP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-11038B

Zelavespib hydrochloride 1 Publications Verification PU-H71 hydrochloride	HSP	Cancer
Zelavespib (PU-H71) hydrochloride is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-11038

Zelavespib 1 Publications Verification PU-H71	HSP	Cancer
Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-N8187

Eupalinolide O	Apoptosis	Cancer
Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells .

HY-11038D

Zelavespib formic 1 Publications Verification PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC₅₀ value of 51 nM for Hsp90 in MDA-MB-468 cells .

HY-101447

SI-2 EPH 116	Src Apoptosis	Cancer
SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, with IC₅₀s ranging from 3-20 nM, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg) .

HY-158170

CDK7-IN-28	CDK	Cancer
CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC₅₀＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-159990

GPX4-IN-15	Glutathione Peroxidase	Cancer
GPX4-IN-15 (Compound C1) is an inhibitor for GPX4, that inhibits 19.8% GPX4 at 1 μM. GPX4-IN-15 inhibits the proliferation of cancer cell MDA-MB-468, BT-549 and MDA-MB-231 with IC₅₀ of 0.86, 0.96 and 0.48 μM .

HY-159576

O-Me Eribulin O-Me B1939; O-Me E7389; O-Me ER-086526	ADC Cytotoxin	Cancer
O-Me Eribulin is a derivative of Eribulin and is an ADC cytotoxin that can be used for ADC synthesis. O-Me Eribulin can inhibit the cell viability of SKBR3, MDA-MB-468, and A549 cells, with IC₅₀ values of 0.2052, 0.1827, and 0.5151 nM, respectively. O-Me Eribulin can be used for tumor research .

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

HY-P10760

PhAc-ALGP-Dox	Peptide-Drug Conjugates (PDCs)	Cancer
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC₅₀ values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .

HY-151630

hCAIX-IN-16	Carbonic Anhydrase	Cancer
hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with K_{i values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .}

HY-168037

PROTAC PIN1 degrader-1	PROTACs PIN1	Cancer
PROTAC PIN1 degrader-1 (compound D4) is a PROTAC targeting PIN1, with a DC50=1.8 nM. The GI50 of PROTAC PIN1 degrader-1 to MDA-MB-468 is >30 μM. PROTAC PIN1 degrader-1 is composed of target protein ligand PIN1 ligand-1 (HY-168038) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part), and PROTAC linker (black part) ^{[1] ^.}

HY-160899A

Thailanstatin A cyclohexane diamine formic	Drug-Linker Conjugates for ADC	Cancer
Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC₅₀ is 0.33 μM), BT474 (IC₅₀ is 0.34 μM), MDA-MB-361-DYT2 (IC₅₀ is 0.88 μM) and MDA-MB-468 (IC₅₀ is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .

HY-145860

PHGDH-IN-2	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-2 is a potent and NAD ⁺ competitive PHGDH inhibitor with an IC₅₀ of 5.2 µM. PHGDH-IN-2 inhibits the serine synthetic pathway in MDA-MB-468 cells. PHGDH-IN-2 inhibits the growth of PHGDH-dependent cancer cells .

HY-147670

TPB15	Hedgehog Smo Gli Apoptosis	Cancer
TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity .

HY-155113

PROTAC Hsp90α degrader 1	PROTACs HSP	Cancer
PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC₅₀s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-162751

Anticancer agent 249	HSP Apoptosis	Cancer
Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC₅₀ of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC₅₀ of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .

HY-152945

Antiproliferative agent-22	NF-κB	Cancer
Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC₅₀ values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .

HY-161456

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

HY-155098

CNBCA	SHP2	Cancer
CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC₅₀ of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study .

HY-160598

Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol	ADC Cytotoxin Topoisomerase	Cancer
Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC₅₀ of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer .

HY-150613

PARP1/BRD4-IN-2	Epigenetic Reader Domain PARP Apoptosis	Cancer
PARP1/BRD4-IN-2 is a potent and selective PARP1 and BRD4 inhibitor with IC₅₀ values of 197 nM and 238 nM, respectively. PARP1/BRD4-IN-2 inhibits DNA damage repair, arrests G0/G1 transition and induces apoptosis. PARP1/BRD4-IN-2 has anti-tumor activity in MDA-MB-468 xenograft mouse model. PARP1/BRD4-IN-2 can be used for researching triple-negative breast cancer (TNBC) .

HY-163709

PROTAC FAK degrader 2	PROTACs FAK	Cancer
PROTAC FAK degrader 2 (Compound F2) is a PROTAC degrader for focal adhesion kinase (FAK), with DC₅₀ of 27.72 and 60.1 nM, for total FAK and phosphorylated p-FAK. PROTAC FAK degrader 2 inhibits cell viability of cancer cells 4T1, MDA-MB-231, MDA-MB-468 and MDA-MB-435, with IC₅₀s of 0.73-5.84 μM. PROTAC FAK degrader 2 reverses the multidrug resistance (MDR) through inhibition of AKT and ERK signaling pathway. PROTAC FAK degrader 2 exhibits antitumor efficacy in HCT/8 xenograft mouse model. (Pink: ligand for target protein Ifebemtinib (HY-122844); Black: linker (HY-Y0681); Blue: ligand for E3 ligase Thalidomide (HY-14658))

HY-155180

FD2056	PI3K	Cancer
FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC₅₀s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC₅₀ of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC₅₀s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Cytotoxin	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-162413

(R)-LW-Srci-8	Src	Cancer
(R)-LW-Srci-8 is a selective covalent inhibitor of c-Src (IC₅₀= 35.83 nM) that disrupts the autophosphorylation of c-Src by targeting its autophosphorylation site (Y419) .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-151888

Anticancer agent 92	Others	Cancer
Anticancer agent 92 (Compound 5f) is an anticancer agent that is nontoxic against noncancerous cells .

HY-N0364

Falcarindiol 1 Publications Verification	Apoptosis Autophagy PPAR	Infection Metabolic Disease Inflammation/Immunology Cancer
Falcarindiol, an orally active polyacetylenic oxylipin, activates PPARγ and increases the expression of the cholesterol transporter ABCA1 in cells. Falcarindiol induces apoptosis and autophagy. Falcarindiol has anti-inflammatory, antifungal, anticancer and antidiabetic properties . Falcarindiol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151632

hCAIX-IN-15	Carbonic Anhydrase	Cancer
hCAIX-IN-15 is a potent hCA IX inhibitor with a K_i value of 38.8 nM. hCAIX-IN-15 shows good broad-spectrum anticancer activity and can be used for cancer research .

HY-149959

Mps1-IN-6	Mps1	Cancer
Mps1-IN-6 is a potent Mps1 inhibitor with an IC₅₀ value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity .

HY-100914

A-7 hydrochloride Ophobolin A	Calmodulin	Cancer
A-7 hydrochloride (Ophobolin A) is a calmodulin antagonist and can be used for the research of cancer .

HY-123524

STAT3-IN-4	STAT	Cancer
STAT3-IN-4 (compound B9) is a STAT3 inhibitor with K_d values for STAT3 (I634S/Q635G) and WT are 22.75 and 4.59 μM, respectively. STAT3-IN-4 can inhibit the proliferation of tumor cells .

HY-129800

CGP78850	Others	Cancer
CGP78850 is a potent and selective competitor of Grb2 SH2-phosphopeptide interactions. CGP78850 can be used for the research of cancer .

HY-120279A

CFI-400437	Polo-like Kinase (PLK)	Cancer
CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC₅₀ of 0.6 nM) .

HY-148570

PHGDH-IN-3	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC₅₀ value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a PARP1/2/CDK12 inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-155339

Anticancer agent 168	Apoptosis DNA/RNA Synthesis	Cancer
Anticancer agent 168 (compound d16) is a inhibitor of DNA2. Anticancer agent 168 induces apoptosis and cell-cycle arrest mainly at S-phase, and exhibits anticancer activities and overcomes chemotherapy resistance in mutp53-bearing cancers .

HY-158649

Fasnall benzenesulfonate	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC₅₀ of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice .

HY-168627

EGFR-IN-135	EGFR	Cancer
EGFR-IN-135 (compound 3d) is a EGFR inhibitor with the IC₅₀ of 0.086 µM. EGFR-IN-135 inhibitor cell growth and arrests the cell cycle at the S phase of reast cancer cell lines .

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-146666

STAT3-IN-9	Apoptosis STAT	Cancer
STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase .

HY-150609

SHP2/CDK4-IN-1	SHP2 Phosphatase CDK	Cancer
SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC₅₀ values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .

HY-103692

STX-0119 2 Publications Verification	STAT	Cancer
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-149847

JH530	Others	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-158377

CDK8/19-IN-2	CDK STAT	Cancer
CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC₅₀ values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research .

HY-W338764

AHR agonist 3	Apoptosis Aryl Hydrocarbon Receptor	Cancer
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .

Cat. No.	Product Name	Target	Research Area

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-P10760

PhAc-ALGP-Dox	Peptide-Drug Conjugates (PDCs)	Cancer
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC₅₀ values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .

Cat. No.	Product Name		Classification

HY-135699

TD52 1 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 1 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MDA-MB-468

Inhibitors & Agonists

Peptides

NaturalProducts

Click Chemistry

Natural
Products